Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 463

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project

Open access
Stiller, C.A., Trama, A., Brewster, D.H., Verne, J., Bouchardy, C., Navarro, C., Chirlaque, M.D., Marcos-Gragera, R., Visser, O., Serraino, D., Weiderpass, E., Dei Tos, A.P., Ascoli, V.·2014·Cancer Epidemiology

Abstract

Kaposi sarcoma (KS) is a virus-related malignancy which most frequently arises in skin, though visceral sites can also be involved. Infection with Kaposi sarcoma herpes virus (KSHV or HHV-8) is required for development of KS. Nowadays, most cases worldwide occur in persons who are immunosuppressed, usually because of HIV infection or as a result of therapy to combat rejection of a transplanted organ, but classic Kaposi sarcoma is predominantly a disease of the elderly without apparent immunosuppression. We analyzed 2667 KS incident cases diagnosed during 1995-2002 and registered by 75 population-based European cancer registries contributing to the RARECARE project. Total crude and age-standardized incidence rate was 0.3 per 100,000 per year with an estimated 1642 new cases per year in the EU27 countries. Age-standardized incidence rate was 0.8 per 100,000 in Southern Europe but below 0.3 per 100,000 in all other regions. The elevated rate in southern Europe was attributable to a combination of classic Kaposi sarcoma in some Mediterranean countries and the relatively high incidence of AIDS in several countries. Five-year relative survival for 2000-2002 by the period method was 75%. More than 10,000 persons were estimated to be alive in Europe at the beginning of 2008 with a past diagnosis of KS. The aetiological link with suppressed immunity means that many people alive following diagnosis of KS suffer comorbidity from a pre-existing condition. While KS is a rare cancer, it has a relatively good prognosis and so the number of people affected by it is quite large. Thus it provides a notable example of the importance of networking in diagnosis, therapy and research for rare cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.canep.2014.09.009

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 463

Metadata

Authors
Stiller, C. A., Trama, A., Brewster, D. H., Verne, J., Bouchardy, C., Navarro, C., Chirlaque, M. D., Marcos-Gragera, R., Visser, O., Serraino, D., Weiderpass, E., Dei Tos, A. P., & Ascoli, V.
Venue
Cancer Epidemiology
Publisher
Elsevier BV
Published
2014-12
Volume
38
Issue
6
Pages
670-678
ISSN
1877-7821 (ISSN-L)
OpenAlex
W2088303301
Cited by
463
References
3
FWCI
14.36
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. https://app.cochat.ai/papers/10.1016/j.canep.2014.09.009
The paper
Stiller, C. A., Trama, A., Brewster, D. H., Verne, J., Bouchardy, C., Navarro, C., Chirlaque, M. D., Marcos-Gragera, R., Visser, O., Serraino, D., Weiderpass, E., Dei Tos, A. P., & Ascoli, V. (2014). Descriptive epidemiology of Kaposi sarcoma in Europe. Report from the RARECARE project. Cancer Epidemiology. https://doi.org/10.1016/j.canep.2014.09.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.